Most symptoms of CRS and neurologic events in ZUMA-3 occurred early and were generally manageable using established guidance1,2

Summary of CRS and neurologic events

No new safety signals were seen at a median study follow-up of 38.7 months4-6


Guidance for monitoring and management of CAR T-related adverse reactions (CRS and neurologic events)1

Two blue and purple infusion icons. Two blue and purple infusion icons.
Ensure that 2 doses of tocilizumab are available for each patient prior to infusion. For more information on CRS and neurologic events management, please see the full Prescribing Information for TECARTUS
Blue and purple calendar icon. Blue and purple calendar icon.
Continue to monitor patients for signs or symptoms of these adverse reactions for 4 weeks postinfusion
Blue and purple treatment center icon. Blue and purple treatment center icon.
Monitor patients daily for at least 14 days postinfusion at the Authorized Treatment Center for signs and symptoms of CRS and neurologic events
Blue and purple cell phone with purple HCP on screen icon. Blue and purple cell phone with purple HCP on screen icon.
Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic events occur at any time

Guidance for monitoring and management of CAR T-related adverse reactions (CRS and neurologic events)1

Two blue and purple infusion icons. Two blue and purple infusion icons.
Ensure that 2 doses of tocilizumab are available for each patient prior to infusion. For more information on CRS and neurologic events management, please see the full Prescribing Information for TECARTUS
Blue and purple treatment center icon. Blue and purple treatment center icon.
Monitor patients daily for at least 14 days postinfusion at the Authorized Treatment Center for signs and symptoms of CRS and neurologic events
Blue and purple calendar icon. Blue and purple calendar icon.
Continue to monitor patients for signs or symptoms of these adverse reactions for 4 weeks postinfusion
Blue and purple cell phone with purple HCP on screen icon. Blue and purple cell phone with purple HCP on screen icon.
Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic events occur at any time

In the ZUMA-3 trial7:

  • Patients with Grade >1 treatment-related CRS or neurologic events were to remain hospitalized until the adverse reaction resolved
  • Discharge occurred only after all treatment-related nonhematologic toxicities returned to Grade ≤1 or baseline

ALL=acute lymphoblastic leukemia; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. 3. Data on file. Kite Pharma, Inc; 2021. 4. Data on file. Kite Pharma, Inc; 2023. 5. Shah BD, Ghobadi A, Oluwole OO, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022;15(1):170. Published online December 10, 2022. doi:10.1186/s13045-022-01379-0 6. Hadjivassileva T, Shah BD, Ghobadi A, et al. Three-year follow-up of brexucabtagene autoleucel, an anti-CD19 chimeric antigen receptor T-cell therapy, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia in ZUMA-3. Poster 34. Poster presented at the 5th European CAR T-cell Meeting; February 9-11, 2023; Rotterdam, The Netherlands. 7. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study – supplementary appendix. Lancet. Published online June 4, 2021. doi:10.1016/S0140-6736(21)01222-8